Abstract: Pulmonary arterial hypertension（PAH） is one of the most severe complications of systemic lupus erythematosus（SLE）, recent studies have emphasized the role which T and B lymphocytes play during the pathogenesis of PAH. Rituximab（RTX）, not only targeting at B lymphocytes, but also been proven to affect T cells, thus could be a potential treatment for SLE-PAH.

Key words: Rituximab, Pulmonary arterial hypertension, Systemic lupus erythematosus